Why—and When—to Use a CDMO

This article is the first part of our “Best Practices in the CDMO Selection Process” series, through which we intend to provide sound advice to agile biotech companies in identifying and selecting the right Contract Development and Manufacturing Organization (CDMO) for advancing the development of their product(s), in conjunction with successfully managing a chosen CDMO to meet the company’s expectations.

Publications
Published on:
August 25, 2022

Pharmaceutical development companies of all sizes frequently outsource their Active Pharmaceutical Ingredient (API) manufacturing to CDMOs for various reasons, including: a) limited internal know-how and capacity to manufacture API according to Good Manufacturing Practice (GMP) or b) to reduce costs and timelines. In this article, we will explore three common reasons why a company might consider engaging a CDMO.

Resource optimization

Early clinical development naturally leads to a fast cycling of projects as candidate molecules are identified and prioritized. Providing staff and capital required for this fluctuation in demand is at the discretion of the company. If a company does invest capital and internal resources to expand its manufacturing capability, it’s best to keep those assets active to offset their high cost.

While cost reduction may seem like a guarantee with a CDMO, a company can truly maximize its savings with a well-planned CDMO selection strategy.
Greater technical expertise and robust infrastructure

Small virtual biotech companies and early-stage clinical companies might have limited internal capabilities and the technical expertise required to manufacture an API. Engaging a CDMO with applicable existing infrastructure and expertise can benefit the company financially while also improving overall product quality and timelines.

Cost reduction

While cost reduction may seem like a guarantee with a CDMO, a company can truly maximize its savings with a well-planned CDMO selection strategy. Initially, a company needs to ensure it’s utilizing its current internal resources to the maximum and only then identify what should be outsourced to a CDMO thus cutting unnecessary spending. More importantly, a carefully planned CDMO selection process can help to identify a CDMO offering the best overall value to the company. While such an identification, evaluation and selection process is not trivial, overall savings can be substantial if the entire process is carried out well.

If you are deciding to outsource your manufacturing or simply looking to obtain insight into the overall CDMO landscape in order to identify the right CDMO for your project, we are here to assist. Our expert team has been helping companies choose the right CDMO for more than a decade and we can be reached here.

Related news

Publications September 14, 2022
Critical Quality Attributes for Drug Products
In this article, we will explore the importance of Critical Quality Attributes (CQAs) in the drug development lifecycle and why it is vital that your selected CDMO is capable of addressing them.
Biotech CDMO Drug Development
Publications September 8, 2022
Best Practices in the CDMO Selection Process
The CDMO series provides sound advice to agile biotech companies in identifying and selecting the right Contract Development and Manufacturing Organization (CDMO) for advancing the(...)
CDMO
Publications September 8, 2022
What to Look for in a CDMO
In this article we will focus on the evaluation of a few identified CDMOs. There are several factors to consider and while some may be subjective to your company’s needs and culture,(...)
Biotech CDMO Contract Development and Manufacturing
News September 6, 2022
Alira Health Expands North American Capabilities with the Acquisition of Artisan Healthcare Consulting
The acquisition of Artisan strengthens and extends Alira Health’s Market Access and Management Consulting advisory practices in North America and globally.
Biotech Market Access Pharma Therapeutics
Publications September 1, 2022
Determine Your Priorities to Finding the Right CDMO
In this article, we will detail the best practices for working with a CDMO to ensure the success of your product development. After having identified the need for engaging a CDMO, the(...)
Biotech CDMO Contract Development and Manufacturing
Publications August 25, 2022
Why—and When—to Use a CDMO
Pharmaceutical development companies of all sizes frequently outsource their Active Pharmaceutical Ingredient (API) manufacturing to CDMOs for various reasons. In this article, we explore(...)
CDMO Pharma Research and Development
Publications June 23, 2022
Developing Data Specialist Talent: Collaboration Is Key
Companies across Pharma and MedTech need talented people to cover the range of data-related challenges. Discover what this means for developing talent throughout the industry.
Data Specialist MedTech Pharma
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.